Biphasic activity of resveratrol on indomethacin-induced gastric ulcers.
Resveratrol showed biphasic activity in indomethacin-induced gastric ulcerated mice. A protective effect at a lower dose (2 mg kg(-1)) and a contraindicative effect at a higher dose of Resveratrol (10 mg kg(-1)) were observed. This phenomenon was possibly controlled by a COX-1 and eNOS balance, which ultimately maintained angiogenesis in Resveratrol-treated pre-ulcerated mice. The lower dose of Resveratrol (2 mg kg(-1)) augmented eNOS expression without altering COX-1 expression, but, at a higher dose (10 mg kg(-1)), Resveratrol predominantly suppressed COX-1 expression, which significantly reduced both PGE2 synthesis and angiogenesis. Thus it ultimately resulted in delay healing of indomethacin-induced gastric ulcers. Hence, it could be concluded that COX-1 and eNOS acted as key regulatory factors switching the biphasic effects of Resveratrol in indomethacin-induced ulcerated mice.
Dey
Anindya
A
Department of Biochemistry, Dr. B.C. Roy Post Graduate Institute of Basic Medical Sciences & I.P.G.M.E. & R., 244B, Acharya Jagadish Chandra Bose Road, Kolkata, West Bengal 700 020, India.
Guha
Prasun
P
Chattopadhyay
Subrata
S
Bandyopadhyay
Sandip K
SK
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity; D000075202:Contraindications; D051545:Cyclooxygenase 1 / Q000378:metabolism*; D007213:Indomethacin / Q000633:toxicity; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D051379:Mice; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism*; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage*; D013276:Stomach Ulcer / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D008565:Membrane Proteins; D013267:Stilbenes; D052250:Nitric Oxide Synthase Type III; C496315:Nos3 protein, mouse; D051545:Cyclooxygenase 1; C496512:Ptgs1 protein, mouse; D000077185:Resveratrol; D007213:Indomethacin